Transformed but Not Cured: The Ethics of Describing Gene-Editing Therapy for Sickle Cell Disease
Jada Wiggleton-Little, Shameka Poetry Thomas, Kristin Walters, Consuela Albright
In December 2023, the Food and Drug Administration approved gene-editing therapies as sickle cell disease treatments. They not only mark a radical scientific innovation for populations living with sickle cell disease, but they have also generated an expectation of a potential cure. This essay, however, cautions against framing gene-editing therapy as a “cure” for sickle cell disease.
Also in this issue:
At Law : Banning Gender-Affirming Treatment for Minors: The Supreme Court Speaks
Rebecca Dresser
Jennifer Saltzstein
Article: Mandated Drug Treatment in the Criminal Legal System—a Blunt but Necessary Tool?
Brendan Saloner
Other Voices
Rethinking Mandated Drug Treatment: Why Expanding Freedom Requires Structural Drug Policy Reform
Tim Holland, Tiffany O'Donnell
Harm Reduction as an Alternative to Mandated Drug Treatment
Elliott J. Liebling
Perspective
Making the Move to a Learning System of Research Ethics
Neal W. Dickert
Table of Contents Hastings Center Report: Vol 56, No 3
For more information, contact:
Susan Gilbert
Director of Communications
The Hastings Center for Bioethics
845-424-4040 x244
gilberts@thehastingscenter.org .
The Hastings Center Report
Commentary/editorial
People